Analysts think GTBP stock price could increase by 5086%
Jun 14, 2024, 6:29 AM
0.00%
What does GTBP do
GT Biopharma, Inc., a clinical-stage biopharmaceutical company based in Brisbane, California, specializes in developing immuno-oncology therapies using its proprietary TriKE NK cell engager platform. Its lead product, GTB-3550, targets CD33-expression in cancer patients and is currently in Phase 1 clinical trials.
3 analysts think GTBP stock price will increase by 5086.44%. The current median analyst target is $153.00 compared to a current stock price of $2.95. The lowest analysts target is $151.50 and the highest analyst target is $157.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.